CSIMarket Company Name, Ticker, Industry, else..
 
Acelyrin Inc   (NASDAQ: SLRN)
Other Ticker:  
 
 
Price: $2.2700 $0.04 1.794%
Day's High: $2.36 Week Perf: 11 %
Day's Low: $ 2.20 30 Day Perf: -0.22 %
Volume (M): 4,077 52 Wk High: $ 7.25
Volume (M$): $ 9,254 52 Wk Avg: $3.88
Open: $2.24 52 Wk Low: $1.85



 Market Capitalization (Millions $) 229
 Shares Outstanding (Millions) 101
 Employees 202
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -269
 Cash Flow (TTM) (Millions $) -206
 Capital Exp. (TTM) (Millions $) 1

Acelyrin Inc
Acelyrin Inc is a company that specializes in providing innovative technological solutions for various industries. They have a team of highly skilled professionals who develop cutting-edge software and hardware products to meet the unique needs of their clients.

The company focuses on delivering efficient and effective solutions that enhance business processes and improve productivity. They offer a range of services including software development, data analytics, cloud computing, cybersecurity, and artificial intelligence.

Acelyrin Inc is known for its commitment to quality and customer satisfaction. They emphasize building long-lasting relationships with their clients by understanding their requirements and delivering solutions that exceed expectations. Their strong technical expertise and industry knowledge enable them to tackle complex challenges and provide innovative solutions.

Overall, Acelyrin Inc is a technology-driven company that aims to empower businesses with advanced technological solutions to help them stay competitive and drive growth in today's digital world.


   Company Address: 4149 Liberty Canyon Road Agoura Hills 91301 CA
   Company Phone Number: 456-4393   Stock Exchange / Ticker: NASDAQ SLRN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.02%    
ABT   -1.94%    
BMY   -5.81%    
JNJ   -4.65%    
MRK   -3.24%    
PFE   -2.32%    
• View Complete Report
   



Shares

ACELYRINs Strategic Move: A Limited-Duration Rights Plan Amid Shareholder Developments

Published Thu, Mar 13 2025 11:01 AM UTC

ACELYRIN Implements Stockholder Rights Plan in Response to Significant Share AccumulationIn a pivotal development for investors and market watchers, ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company specializing in the advancement of transformative medicines within the immunology sector, has recently announced the adoption of a limited-duration stockhold...
Merger and Acquisition

Navigating New Frontiers: Acelyrin and Alumis Forge Strategic Merger to Innovate Immunology and Reinforce Financial Stability,

Published Tue, Mar 4 2025 2:01 PM UTC

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger: A Look at the Combined Entity?s FutureIn the rapidly evolving world of healthcare technology, strategic mergers and acquisitions are pivotal in defining the competitive landscapes and clinical advancements. Recently, on February 21, 2025, Acelyrin Inc (NASDAQ: SLRN)?a technology company known...
Stock Market Announcement

ACELYRIN Receives Acquisition Offer Amid Strategic Mergers in Immunology Sector

Published Fri, Feb 21 2025 2:00 AM UTC

Los Angeles, CA ACELYRIN, INC. (Nasdaq: SLRN), a key player in the late-stage clinical biopharmaceutical landscape, has confirmed the receipt of an unsolicited acquisition proposal from Concentra Biosciences, LLC. The offer, publicly disclosed this week, values ACELYRIN at $3.00 per share in cash, along with a contingent value right designed to benefit shareholders from fu...
Merger and Acquisition

Navigating the Complexities of Biopharma: Acelyrin?s Setbacks and Alumis? Promising Trials

Published Thu, Feb 6 2025 9:15 PM UTC

Acelyrin Inc. (NASDAQ: SLRN) is currently facing a turbulent period in its journey through the biopharma landscape. While the company has made strides in developing innovative technology geared towards enhancing patient outcomes and improving healthcare efficiency, it now finds itself contending with market challenges and setbacks associated with its Izokibep Uveitis trial. ...
Clinical Study

Navigating Adversity ACELYRIN, INC. Faces Setbacks in Izokibep Uveitis Trial and Market Performance,

Published Mon, Dec 30 2024 3:11 AM UTC

ACELYRIN, INC. Announces Suboptimal Outcomes in Izokibep Uveitis Trial and Market Performance In the ever-evolving sphere of pharmaceutical research, each clinical trial is a stepping stone to potential medical breakthroughs, albeit not without its share of setbacks. Recently, ACELYRIN, INC. a biopharmaceutical company at the forefront of immunological and inflammatory resea...





  Acelyrin Inc Outlook

On May 9 2024 the Acelyrin Inc provided following guidance

Acelyrin Inc. has provided a business update regarding the progress of their clinical trials. The company has successfully completed enrollment in the Phase 3 trial for izokibep in hidradenitis suppurativa. Additionally, enrollment in the Phase 2b/3 trial for uveitis is expected to be completed by the end of this month.

The top line data for both trials is now anticipated to be available by the end of the third quarter and fourth quarter of 2024, respectively. These milestones mark significant progress in the development of Acelyrin Inc.'s potential treatments for these challenging medical conditions.

The company remains committed to advancing research and development efforts to bring innovati...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com